Anti-Human HER2 (Trastuzumab Biosimilar), L234A L235A P329G (LALAPG) Fc Silent Mutant
Catalog #500062
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500062 | 1 mg | $650.00 |
Product Details
Trastuzumab Biosimilar is a research-grade monoclonal antibody designed to target HER2 (ErbB2/CD340), a receptor tyrosine kinase overexpressed in certain cancers, including HER2-positive breast cancer. It functions similarly to the therapeutic Trastuzumab (Herceptin®) by binding to HER2, inhibiting tumor cell proliferation, and triggering antibody-mediated cytotoxicity.
Specifications
| Clone | Trastuzumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1, L234A L235A P329G (LALAPG) |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 6.0 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | A431 cells overexpressing human EGFR |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |